Purpose: There is growing agreement that definitions of "recovery" in bipolar-I disorder (BP-I) should include functional outcomes beyond sustained symptomatic remission. In this post-hoc analysis, we assessed functional recovery rates according to the validated Functioning Assessment Short Test (FAST) in participants with BP-I after 52 weeks of maintenance treatment with aripiprazole once monthly (AOM).
Introduction
While many people living with bipolar disorders regain psychosocial functioning upon symptomatic remission, the majority suffer persistent functional difficulties, often despite adequate control of their core affective symptoms. Such functional deficits include problems in their ability to work, study, live independently, maintain interpersonal relationships and participate in recreational activities. 1 Mood stabilizers and/or atypical antipsychotics are well accepted as the mainstays of bipolar-I disorder (BP-I) treatment. [2] [3] [4] Compared with their oral counterparts, longacting injectable (LAI) atypical antipsychotic formulations allow for better adherence with more consistent dosing 2, 4 and have recently shown to be more effective in preventing hospitalization of BP-I patients due to mental or physical illness. 5 Aripiprazole 400 mg once monthly (AOM 400) is an LAI approved by the US Food and Drug Administration as maintenance monotherapy treatment for BP-I. 6 Results from recent placebo-controlled 7 and open-label 8 studies
show that maintenance treatment with AOM 400 delays the time to mood episode recurrence and is safe and welltolerated.
There is growing agreement that definitions of "functional recovery" in bipolar disorders should include functional outcomes beyond sustained symptomatic remission. 9 Both studies of AOM 400 as maintenance treatment used the Functioning Assessment Short Test (FAST), which was developed as a short simple interview-administered instrument for use in patients with psychiatric disorders, and especially bipolar disorders. 10 The FAST has been shown to have strong psychometric properties and is able to detect differences between euthymic and acute patients with bipolar disorder. 10 We have previously reported maintenance of improvement in FAST scores over 52 weeks in the AOM group of the placebo-controlled study. 11 Taking into account the FAST cut off scores proposed by Rosa et al, 10 we defined recovery as a FAST total score ≤11 for ≥8 consecutive weeks and assessed the rates of functional recovery in participants with BP-I after long-term (52-week) treatment with AOM 400.
Materials and methods
The efficacy and safety of AOM 400, given every 4 weeks, as maintenance treatment of BP-I was investigated in two, 52-week studies, the full methodologic details of which have been previously published:
1. A placebo-controlled, double-blind, randomizedwithdrawal study (NCT01567527) conducted in 103 sites in 7 countries. 7 2. An open-label, multicenter study (NCT01710709) conducted in 149 sites in 10 countries. 8 Both studies 7, 8 were conducted in compliance with the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice guidelines for conducting, recording and reporting trials, as well as for archiving essential documents. Consistent with ethical principles for the protection of human research subjects, no trial procedures were performed on trial candidates until written consent had been obtained from them. The informed consent form , protocol and amendments for this trial were submitted to and approved by the institutional review board (IRB) or independent ethics committee (IEC) for each respective trial site or country (Table S1 ).
Study design
Study designs are summarized in Figure 1 . Briefly, in the randomized-withdrawal study, participants completed oral aripiprazole conversion and stabilization phases if needed, followed by a single-blind AOM 400 stabilization phase. Those meeting stability criteria (outpatient status, Young Mania Rating Scale [YMRS] total score ≤12, Montgomery-Asberg Depression Rating Scale [MADRS] total score ≤12 and no active suicidality) were randomized to double-blind treatment with AOM 400 or placebo for 52 weeks. The open-label study had two protocols, depending on whether the participants were de novo or had rolled-over from the randomized-withdrawal study. Whereas rollover participants began the 52-week, open-label AOM 400 maintenance phase immediately after completing the prior double-blind maintenance phase (AOM 400 or placebo), de novo participants entered a 4-to 12-week oral aripiprazole stabilization phase before entering the open-label maintenance phase. If de novo participants were receiving a non aripiprazole antipsychotic medication before enrollment, a 4-to 6-week oral aripiprazole cross-titration phase was implemented before the oral aripiprazole stabilization phase.
Participants
Both studies enrolled outpatients (18-65 years) who had a clinical diagnosis of BP-I (DSM, 1994), and who were further verified by the Mini-International Neuropsychiatric Interview.
Participants included in the open-label study were rolled over from the double-blind study or were AOM 400 treatmentnaive and enrolled de novo.
All participants in the randomized-withdrawal study and new participants recruited to the open-label study were eligible for the trial if they had experienced ≥1 previous manic or mixed episode with manic symptoms of sufficient severity to require hospitalization, treatment with a mood stabilizer, or treatment with an antipsychotic agent. Study entry criteria were similar, except that the randomized-withdrawal study required participants to have a YMRS score >20 and excluded participants with a mixed or depressive episode, and the open-label study had no YMRS criterion and only excluded participants with a depressive episode. The open-label study also included rollover participants, who had completed the maintenance phase of the randomized-withdrawal study (AOM 400 or placebo) without recurrence of a mood episode. Participants previously on placebo had prior exposure to AOM 400 due to the 12-to 28-week AOM 400 stabilization phase.
Analysis of functional recovery
These analyses included all participants (both studies) who received maintenance study treatment and had ≥1 post baseline FAST assessment. Functioning was assessed using the FAST (Table S2) , where trained investigators ranked the participant's level of difficulty from 0 (no difficulty) to 3 (severe difficulty). Domains are based on grouping of the 24 individual items: autonomy (4 items), occupational functioning (5 items), cognitive functioning (5 items), financial issues (2 items), interpersonal relationships (6 items) and leisure time (2 items). The FAST total score (range 0-72) is calculated as the sum of each of the 24 item scores, with higher scores representing worse function. 10 Any one missing score led to a missing total score. In addition, our definition included a minimum duration of 8 consecutive weeks to ensure that transient fluctuations were not designated as recovery. 12 Functional recovery was thus defined post-hoc as a FAST total score of ≤11 for 8 consecutive weeks. FAST total and domain scores (LOCF) were summarized at baseline and Week 52 of the respective maintenance phases using mean and SD for 1) all participants included in the analyses of FAST data and 2) those participants who met criteria for functional recovery. Between-group differences were derived from an ANOVA model with treatment and region as baseline factors.
Results

Patient disposition and baseline characteristics
Of the 266 participants entered into the randomizedwithdrawal phase of the placebo-controlled study, 116 received AOM 400 and 113 received placebo and had Screening (n=958) 6 weeks a Patients were stabilized for a manic episode prior to randomization; therefore recurrences of manic episodes were expected to predominate during the study. b patients were switched to oral aripiprazole if not already receiving it.
c the target dose in the oral stabilization phase was 15-30mg/day. d the AOM-400 stabilization phase was single blind; if patients were stable for 8 consecutive weeks, they progressed to double-blind, randomized maintenace treatement.
e oral aripiprazole continued for 14 days following the first AOM 400 injection f the dose of AOM could be changed to 300 mg for tolerability. a During the cross-titration phase, patients were switched to oral aripiprzole if not already receiving it.
b the target dose in the stabilization phase was 15-30mg/day; if the patients was stable at one biweekly vists, they progressed to the AOM 400 stabilization phase.
c patients who had first participated in the randomized withdrawal study (AOM 400 And placebo, n=81) were subesquently enrolled in the open-label study entered directly into the maintenance phase of the open-label study. Together with the de nono patients entering from the stabilization phase (n=321) this summed up to 402 patients in maintenance phase. Dose reductions to 300 mg were permitted for tolerbility during the maintenance phase. ≥1 post-baseline FAST assessment. In the open-label study, 402 of the original 464 participants entering the maintenance phase had ≥1 post baseline FAST assessment (321 de novo participants, 81 rollover participants). Overall 52/81 of the rollover participants had already received treatment with AOM 400 for up to 52 weeks at baseline in the placebo-controlled, doubleblind study (for these participants total treatment duration, therefore, ranged between 52 and 80 weeks).
Baseline characteristics for the full populations of the two studies have been previously published. In brief, 57.5% of participants (n=266) in the randomized-withdrawal study were female, the mean±SD age was 40.6 ± 11.0 years and age at first manic episode was 25.0 ± 10.1 years; participants had 3.5 ± 4.0 prior hospitalizations for a mood episode. The mean YMRS total score was 2.8 ± 3.3, MADRS score was 2.7 ± 3.4 and FAST score was 15.4 ± 12.7 (Phase D baseline). 7 For the open-label study, 57.8% of participants (n=464) were female, the mean age was 41.1 ± 11.8 years and age at first BP-I diagnosis was 29.1 ± 11.7 years. The mean YMRS total score was 2.3 ± 2.9 and MADRS score was 3.2 ± 3.2. In the open-label study, functional recovery as measured by FAST after 52 weeks of treatment was achieved by 36% of de novo participants (n=116) (Figure 2 
open-label AOM 400, including 8 who met criteria for recovery in both studies.
FAST scores
In the randomized-withdrawal study, FAST total scores were generally maintained in the group of participants who received AOM 400 (mean±SD score of 15 
For those participants who met criteria for functional recovery, mean ± SD FAST total scores numerically improved from 5.47 ± 5.50 at baseline to 3.51 ± 3.62 at Week 52 in the AOM 400 group and from 4.44 ± 4.23 at baseline to 2.75 ± 2.86 at Week 52 in the placebo group. Analyses by domain are provided in Table 1 .
In the open-label study, de novo participants significantly improved from a mean of 17.90 ± 13.51 at baseline to 14.02 ± 12.02 at the end of the 4-to 12-week stabilization phase (p<0.00001, one-sided Z test). FAST total scores were then maintained during the 52-week maintenance phase (from 14.02 ± 12.02 to 13.98 ± 13.05 in de novo participants and from 12.89 ± 12.22 to 13.95 ± 13.46 in rollover participants). For those participants who met criteria for functional recovery, mean FAST total scores (baseline of maintenance phase/Week 52) were 4.09 ± 4.00/3.59 ± 3.39 in the de novo group and 3.71 ± 3.00/ 3.54 ± 3.35 in the rollover group.
Discussion
To the best of our knowledge, this is the first analysis of clinical trials to use FAST thresholds as a definition of functional recovery and highlight the scale's utility in understanding the effectiveness of an intervention. Our analyses of two long-term studies demonstrate that maintenance treatment with AOM 400 can help patients living with BP-I achieve long-term functional recovery. Overall, 30-43% of participants who received AOM 400 for at least 52 weeks achieved long-term functional recovery as determined by a FAST score of ≤11 for at least 8 consecutive weeks.
Although the threshold for recovery used in these analyses was initially based on the FAST validation studies, which found that a score of >11 offers the best discriminant sensitivity and specificity, 10 more recent studies support its use as a relatively conservative definition. According to Bonnin et al, euthymic BP-I outpatients in this category "present good functioning in all areas, they live independently, they work and they have a meaningful social engagement". 13 In terms of recovery rates, our exploratory analyses of the randomized-withdrawal study did not show statistical separation from placebo. This is likely due, in part, to a survivor effect of the study design, where participants who initially had marked functional improvement and then stabilization (over 12-28 weeks) were able to remain functionally recovered, even when later randomized to placebo. Nevertheless, as previously reported, participants randomized to placebo showed a significant worsening in FAST scores relative to AOM and a higher risk of relapse.
11
Overall, at least 57% of the participants who met criteria for functional recovery with AOM 400 maintenance treatment during the placebo-controlled study (and 87% of those who also chose to "roll over" to open-label treatment) remained recovered after completing the subsequent open-label study (ie, after 2 years of stable treatment). Of note, a small proportion of participants did not meet functional recovery criteria with active maintenance treatment during the first year, but did during the second year, thus supporting the idea that functional recovery takes longer to achieve than symptom recovery.
14 Here, it is important to acknowledge that the entire rollover subgroup was highly enriched for patients who responded to and tolerated AOM treatment (during the stabilization phase for placebo patients and during the stabilization plus maintenance phases for AOM 400 patients). Indeed, due to the enriched discontinuation study designs, the generalizability of all results presented herein is limited to patients experiencing a manic episode and stabilized on AOM 400. In terms of the maintenance effect (in both studies), there were only small changes in domain scores, with all functional domains remaining relatively stable with AOM 400 treatment. Likewise, all FAST domains appeared to remain similarly stable in the subgroup of participants who had functionally recovered. Subgroup analyses of the functionally "recovered" participants showed that mean FAST total scores were already <6 at baseline of the maintenance phase, which is similar to a control group of participants without bipolar disorder (mean of 5.93). 15 The rates of functional recovery seen with long-term AOM treatment are in line with or slightly higher than those previously reported after 52 weeks of olanzapine treatment. 16 However, it should also be noted that the olanzapine study defined functional recovery using a combination of the psychosocial functioning sub scale of the SF-36 and work status and disability support measures -the comparability of which with the validated FAST scale is unknown.
Limitations of this study include the post-hoc nature of the recovery rate analyses and the lack of a blinded comparator in the open-label study. Whereas the minimum duration of 8 consecutive weeks could be considered relatively short, 9 we based our definition to be consistent with the recommendations of the International Society for 
Conclusion
Functional recovery is beginning to be considered equally as important as symptomatic recovery, since key goals for patients and relatives are to fulfill role expectations at work/school and home and to maintain good relationships. [18] [19] [20] Almost all individuals with bipolar disorders require maintenance treatment to prevent subsequent episodes, reduce residual symptoms and restore functioning. 4 The results of this study demonstrate the utility of a FAST total score of ≤11 for 8 consecutive weeks as a definition of functional recovery in BP-I and highlight the possibility of achieving this ambitious treatment goal with effective treatment. 
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